-+ 0.00%
-+ 0.00%
-+ 0.00%

ZENTALIS PHARMACEUTICALS, INC. : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM VS MARKET PERFORM RATING; TARGET PRICE $8 VS $4

Reuters·10/05/2026 10:07:42

Please log in to view news